ImaginAb, Inc., signs multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited (Takeda) focused on furthering the clinical development of ImaginAb’s CD8 ImmunoPET technology.
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, today announces that its Chief Executive Officer, Ian Wilson, will present an update on ImaginAb and progress achieved with the CD8 ImmunoPET minibody at the upcoming Innovation Showcase 2019 on Monday, October 14, 2019, at The Lundquist Institute (formerly LA BioMed),1124 West Carson Street, Torrance, CA.
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM). The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting[i]" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, is delighted to be part of ‘Immune-Image,’ the Innovative Medicines Initiative Joint Undertaking (IMI2 JU) project, launching today and which includes top academic institutions, companies, and a patient organization. The project has been awarded a €30 million grant for an initial period of five years to support research into novel tracer strategies for clinical imaging of immune cell dynamics.
ImaginAb celebrates the first screenings of Science Advisory Board member Dr. James Allison’s gripping documentary, Breakthrough, chronicling his discovery of the ground-breaking medicine that would become pivotal in the development of immunotherapy treatments for cancer.
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). This study is a collaboration between UAB’s Division of Hematology and Oncology and Division of Molecular Imaging and Therapeutics, reflecting UAB’s commitment to world-class research and clinical care.